|
1
|
Renard AJ, Veth RP, Schreuder HW,
Pruszczynski M, Bökkerink JP, van Hoesel QG and van Der Staak FJ:
Osteosarcoma: Oncologic and functional results. A single
institutional report covering 22 years. J Surg Oncol. 72:124–129.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrari S, Smeland S, Mercuri M, Bertoni
F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini
G, et al: Neoadjuvant chemotherapy with high-dose Ifosfamide,
high-dose methotrexate, cisplatin and doxorubicin for patients with
localized osteosarcoma of the extremity: A joint study by the
Italian and Scandinavian Sarcoma Groups. J Clin Oncol.
23:8845–8852. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kager L, Zoubek A, Dominkus M, Lang S,
Bodmer N, Jundt G, Klingebiel T, Jürgens H, Gadner H and Bielack S:
COSS Study Group: Osteosarcoma in very young children: Experience
of the cooperative osteosarcoma study group. Cancer. 116:5316–5324.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lewis VO: What's new in musculoskeletal
oncology. J Bone Joint Surg Am. 89:1399–1407. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stiller CA, Bielack SS, Jundt G and
Steliarova-Foucher E: Bone tumours in European children and
adolescents, 1978–1997. Report from the automated childhood cancer
information system project. Eur J Cancer. 42:2124–2135. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bacci G, Briccoli A, Ferrari S, Longhi A,
Mercuri M, Capanna R, Donati D, Lari S, Forni C and DePaolis M:
Neoadjuvant chemotherapy for osteosarcoma of the extremity:
Long-term results of the Rizzoli's 4th protocol. Eur J Cancer.
37:2030–2039. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bacci G, Briccoli A, Rocca M, Ferrari S,
Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, et
al: Neoadjuvant chemotherapy for osteosarcoma of the extremities
with metastases at presentation: Recent experience at the Rizzoli
Institute in 57 patients treated with cisplatin, doxorubicin and a
high dose of methotrexate and ifosfamide. Ann Oncol. 14:1126–1134.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nestle FO, Alijagic S, Gilliet M, Sun Y,
Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of
melanoma patients with peptide- or tumor lysate-pulsed dendritic
cells. Nat Med. 4:328–332. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Berntsen A, Geertsen PF and Svane IM:
Therapeutic dendritic cell vaccination of patients with renal cell
carcinoma. Eur Urol. 50:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suminoe A, Matsuzaki A, Hattori H, Koga Y
and Hara T: Immunotherapy with autologous dendritic cells and tumor
antigens for children with refractory malignant solid tumors.
Pediatr Transplant. 13:746–753. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Campbell CJ, Cohen J and Enneking WF:
Editorial: New therapies for osteogenic sarcoma. J Bone Joint Surg
Am. 57:143–144. 1975.PubMed/NCBI
|
|
12
|
Kawaguchi S, Wada T, Tsukahara T, Ida K,
Torigoe T, Sato N and Yamashita T: A quest for therapeutic antigens
in bone and soft tissue sarcoma. J Transl Med. 3:312005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thurner B, Haendle I, Röder C, Dieckmann
D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von
den Driesch P, et al: Vaccination with mage-3A1 peptide-pulsed
mature, monocyte-derived dendritic cells expands specific cytotoxic
T cells and induces regression of some metastases in advanced stage
IV melanoma. J Exp Med. 190:1669–1678. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meyers PA, Schwartz CL, Krailo MD, Healey
JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM,
Harris M, et al: Osteosarcoma: The addition of muramyl tripeptide
to chemotherapy improves overall survival-a report from the
Children's Oncology Group. J Clin Oncol. 26:633–638. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Palmerini E, Staals EL, Ferrari S, Rinaldi
R, Alberghini M, Mercuri M and Bacci G: Nonresectable multiple lung
metastases of high-grade osteosarcoma of the humerus: Stable after
twelve years. A case report. J Bone Joint Surg Am. 90:2240–2244.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inaba K, Inaba M, Romani N, Aya H, Deguchi
M, Ikehara S, Muramatsu S and Steinman RM: Generation of large
numbers of dendritic cells from mouse bone marrow cultures
supplemented with granulocyte/macrophage colony-stimulating factor.
J Exp Med. 176:1693–1702. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiang CL, Hagemann AR, Leskowitz R, Mick
R, Garrabrant T, Czerniecki BJ, Kandalaft LE, Powell DJ Jr and
Coukos G: Day-4 myeloid dendritic cells pulsed with whole tumor
lysate are highly immunogenic and elicit potent anti-tumor
responses. PLoS One. 6:e287322011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hatfield P, Merrick AE, West E, O'Donnell
D, Selby P, Vile R and Melcher AA: Optimization of dendritic cell
loading with tumor cell lysates for cancer immunotherapy. J
Immunother. 31:620–632. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alaniz L, Rizzo MM and Mazzolini G:
Pulsing dendritic cells with whole tumor cell lysates. Methods Mol
Biol. 1139:27–31. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kandalaft LE, Powell DJ Jr, Chiang CL,
Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA,
et al: Autologous lysate-pulsed dendritic cell vaccination followed
by adoptive transfer of vaccine-primed ex vivo co-stimulated T
cells in recurrent ovarian cancer. Oncoimmunology. 2:e226642013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kozawa E, Sugiura H, Wasa J, Kohyama K,
Yamada K, Nishioka A, Nishida Y, Ishiguro N and Taguchi O:
Suppression of tumour metastasis in a murine osteosarcoma model
with anti-CD25 monoclonal antibody treatment. Anticancer Res.
30:5019–5022. 2010.PubMed/NCBI
|
|
22
|
Thomas-Kaskel AK, Zeiser R, Jochim R,
Robbel C, Schultze-Seemann W, Waller CF and Veelken H: Vaccination
of advanced prostate cancer patients with PSCA and PSA
peptide-loaded dendritic cells induces DTH responses that correlate
with superior overall survival. Int J Cancer. 119:2428–2434. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Napoletano C, Pinto D, Bellati F, Taurino
F, Rahimi H, Tomao F, Panici PB, Rughetti A, Frati L and Nuti M: A
comparative analysis of serum and serum-free media for generation
of clinical grade DCs. J Immunother. 30:567–576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Coester C, Nayyar P and Samuel J: In
vitro uptake of gelatin nanoparticles by murine dendritic cells
and their intracellular localisation. Eur J Pharm Biopharm.
62:306–314. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Araki H, Katayama N, Mitani H, Suzuki H,
Nishikawa H, Masuya M, Ikuta Y, Hoshino N, Miyashita H, Nishii K,
et al: Efficient ex vivo generation of dendritic cells from CD14+
blood monocytes in the presence of human serum albumin for use in
clinical vaccine trials. Br J Haematol. 114:681–689. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mahdian R, Kokhaei P, Najar HM, Derkow K,
Choudhury A and Mellstedt H: Dendritic cells, pulsed with lysate of
allogeneic tumor cells, are capable of stimulating MHC-restricted
antigen-specific antitumor T cells. Med Oncol. 23:273–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vegh Z and Mazumder A: Generation of tumor
cell lysate-loaded dendritic cells preprogrammed for IL-12
production and augmented T cell response. Cancer Immunol
Immunother. 52:67–79. 2003.PubMed/NCBI
|
